Cargando…
Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production
Tetanus toxoid (TTd) plays an important role in the pharmaceutical world, especially in vaccines. The toxoid is obtained after formaldehyde treatment of the tetanus toxin. In parallel, current emphasis in the drug discovery field is put on producing well-defined and safer drugs, explaining the inter...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227095/ https://www.ncbi.nlm.nih.gov/pubmed/35745675 http://dx.doi.org/10.3390/ph15060756 |
_version_ | 1784734078304518144 |
---|---|
author | Bayart, Caroline Mularoni, Angélique Hemmani, Nada Kerachni, Soumeya Jose, Joachim Gouet, Patrice Paladino, Joseph Le Borgne, Marc |
author_facet | Bayart, Caroline Mularoni, Angélique Hemmani, Nada Kerachni, Soumeya Jose, Joachim Gouet, Patrice Paladino, Joseph Le Borgne, Marc |
author_sort | Bayart, Caroline |
collection | PubMed |
description | Tetanus toxoid (TTd) plays an important role in the pharmaceutical world, especially in vaccines. The toxoid is obtained after formaldehyde treatment of the tetanus toxin. In parallel, current emphasis in the drug discovery field is put on producing well-defined and safer drugs, explaining the interest in finding new alternative proteins. The tetanus toxin fragment C (TTFC) has been extensively studied both as a neuroprotective agent for central nervous system disorders owing to its neuronal properties and as a carrier protein in vaccines. Indeed, it is derived from a part of the tetanus toxin and, as such, retains its immunogenic properties without being toxic. Moreover, this fragment has been well characterized, and its entire structure is known. Here, we propose a systematic review of TTFC by providing information about its structural features, its properties and its methods of production. We also describe the large uses of TTFC in the field of drug discovery. TTFC can therefore be considered as an attractive alternative to TTd and remarkably offers a wide range of uses, including as a carrier, delivery vector, conjugate, booster, inducer, and neuroprotector. |
format | Online Article Text |
id | pubmed-9227095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92270952022-06-25 Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production Bayart, Caroline Mularoni, Angélique Hemmani, Nada Kerachni, Soumeya Jose, Joachim Gouet, Patrice Paladino, Joseph Le Borgne, Marc Pharmaceuticals (Basel) Review Tetanus toxoid (TTd) plays an important role in the pharmaceutical world, especially in vaccines. The toxoid is obtained after formaldehyde treatment of the tetanus toxin. In parallel, current emphasis in the drug discovery field is put on producing well-defined and safer drugs, explaining the interest in finding new alternative proteins. The tetanus toxin fragment C (TTFC) has been extensively studied both as a neuroprotective agent for central nervous system disorders owing to its neuronal properties and as a carrier protein in vaccines. Indeed, it is derived from a part of the tetanus toxin and, as such, retains its immunogenic properties without being toxic. Moreover, this fragment has been well characterized, and its entire structure is known. Here, we propose a systematic review of TTFC by providing information about its structural features, its properties and its methods of production. We also describe the large uses of TTFC in the field of drug discovery. TTFC can therefore be considered as an attractive alternative to TTd and remarkably offers a wide range of uses, including as a carrier, delivery vector, conjugate, booster, inducer, and neuroprotector. MDPI 2022-06-17 /pmc/articles/PMC9227095/ /pubmed/35745675 http://dx.doi.org/10.3390/ph15060756 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bayart, Caroline Mularoni, Angélique Hemmani, Nada Kerachni, Soumeya Jose, Joachim Gouet, Patrice Paladino, Joseph Le Borgne, Marc Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production |
title | Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production |
title_full | Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production |
title_fullStr | Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production |
title_full_unstemmed | Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production |
title_short | Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production |
title_sort | tetanus toxin fragment c: structure, drug discovery research and production |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227095/ https://www.ncbi.nlm.nih.gov/pubmed/35745675 http://dx.doi.org/10.3390/ph15060756 |
work_keys_str_mv | AT bayartcaroline tetanustoxinfragmentcstructuredrugdiscoveryresearchandproduction AT mularoniangelique tetanustoxinfragmentcstructuredrugdiscoveryresearchandproduction AT hemmaninada tetanustoxinfragmentcstructuredrugdiscoveryresearchandproduction AT kerachnisoumeya tetanustoxinfragmentcstructuredrugdiscoveryresearchandproduction AT josejoachim tetanustoxinfragmentcstructuredrugdiscoveryresearchandproduction AT gouetpatrice tetanustoxinfragmentcstructuredrugdiscoveryresearchandproduction AT paladinojoseph tetanustoxinfragmentcstructuredrugdiscoveryresearchandproduction AT leborgnemarc tetanustoxinfragmentcstructuredrugdiscoveryresearchandproduction |